Aura Biosciences Inc(AURA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:01 PM ET (Korea 10/29 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.78 | Insider Own | 59.8% | Shs Outstand | 103.5M | Perf Week | -3.96% |
| Market Cap | 0.65B | Forward P/E | - | EPS next Y | 8.84% | Insider Trans | -10.06% | Shs Float | 41.7M | Perf Month | 2.44% |
| Enterprise Value | 0.35B | PEG | - | EPS next Q | -0.37 | Inst Own | 63.29% | Short Float | 26.11% | Perf Quarter | -10.13% |
| Income | -0.13B | P/S | - | EPS this Y | 5.38% | Inst Trans | 34.6% | Short Ratio | 12.91 | Perf Half Y | -9.48% |
| Sales | 0.00B | P/B | 2.07 | EPS next 5Y | 12.07% | ROA | -47.42% | Short Interest | 10.89M | Perf YTD | 15.6% |
| Book/sh | 3.05 | P/C | 2.02 | EPS past 3/5Y | 3.57% -11.28% | ROE | -53.49% | 52W High | -33.93% ($9.53) | Perf Year | 3.28% |
| Cash/sh | 3.12 | P/FCF | - | Sales past 3/5Y | - | ROIC | -39.87% | 52W Low | 33.19% ($4.73) | Perf 3Y | -13.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 9.05% | Gross Margin | - | Volatility(W/M) | 3.84% 4.42% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.29 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.82 | EPS Q/Q | -3.31% | Profit Margin | - | RSI (14) | 46.41 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.82 | Sales Q/Q | - | SMA20 | -0.22% ($6.31) | Beta | 0.41 | Target Price | $16.6 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/11 | SMA50 | -7.05% ($6.78) | Rel Volume | 0.81 | Prev Close | $6.18 |
| Employees | 113 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | -28% - | SMA200 | -5.96% ($6.7) | Avg Volume(3M) | 0.84M | Price | $6.3 |
| IPO | 2021/10/29 | Option/Short | Yes/Yes | Trades | 4418 | Volume | 680,269 | Change | 1.94% |
🔬 Aura Biosciences (AURA) is a US clinical-stage biotech company developing virus-like particle (VLP)-based anticancer therapeutics. Its virus-like drug conjugate (VDC) platform targets ocular and urologic tumors, with its lead candidate, bel-sar, being developed for the treatment of choroidal melanoma.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
Traded about as much as usual. That is 81% of its average volume.
AURA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +5.4% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be -13.1%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #197 of 594 in the industry
Based on market cap of $653M.
FAQ
What kind of company is AURA?
AURA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AURA?
The market cap of AURA is approximately $653M, ranking 2,942 within its sector.
What is the 52-week high and low for AURA?
AURA has recorded a 52-week high of $9.53 and a low of $4.73.
